<?xml version='1.0' encoding='utf-8'?>
<document id="22811345"><sentence text="Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors."><entity charOffset="45-62" id="DDI-PubMed.22811345.s1.e0" text="mycophenolic acid" /></sentence><sentence text="To evaluate the incidence of gastrointestinal (GI) complications in solid organ transplant (SOT) recipients, impact of the complications on transplant outcomes, and the potential interactions between mycophenolic acid (MPA) derivatives and proton pump inhibitors (PPIs)"><entity charOffset="200-217" id="DDI-PubMed.22811345.s2.e0" text="mycophenolic acid" /><entity charOffset="219-222" id="DDI-PubMed.22811345.s2.e1" text="MPA" /><pair ddi="false" e1="DDI-PubMed.22811345.s2.e0" e2="DDI-PubMed.22811345.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22811345.s2.e0" e2="DDI-PubMed.22811345.s2.e1" /></sentence><sentence text="" /><sentence text="An unrestricted literature search (1980-January 2012) was performed with MEDLINE and EMBASE using the following key words: drug-drug interaction, enteric-coated mycophenolic acid, GI complications, mycophenolate mofetil, solid organ transplant, and proton pump inhibitor, including individual agents within the class"><entity charOffset="161-178" id="DDI-PubMed.22811345.s4.e0" text="mycophenolic acid" /><entity charOffset="198-219" id="DDI-PubMed.22811345.s4.e1" text="mycophenolate mofetil" /><pair ddi="false" e1="DDI-PubMed.22811345.s4.e0" e2="DDI-PubMed.22811345.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22811345.s4.e0" e2="DDI-PubMed.22811345.s4.e1" /></sentence><sentence text=" Abstracts from scientific meetings were also evaluated" /><sentence text=" Additionally, reference citations from identified publications were reviewed" /><sentence text="" /><sentence text="Relevant English-language, original research articles and review articles were evaluated if they focused on any of the topics identified in the search or included substantial content addressing GI complications in SOT recipients or drug interactions" /><sentence text="" /><sentence text="GI complications are frequent among SOT recipients, with some studies showing prevalence rates as high as 70%" /><sentence text=" Transplant outcomes among renal transplant recipients are significantly impacted by GI complications, especially in patients requiring immunosuppressant dosage reductions or premature discontinuation" /><sentence text=" To this end, PPI use among patients receiving transplants is common" /><sentence text=" Recent data demonstrate that PPIs significantly reduce the overall exposure to MPA after oral administration of mycophenolate mofetil"><entity charOffset="113-134" id="DDI-PubMed.22811345.s13.e0" text="mycophenolate mofetil" /><entity charOffset="80-100" id="DDI-PubMed.22811345.s13.e1" text="MPA" /><pair ddi="false" e1="DDI-PubMed.22811345.s13.e1" e2="DDI-PubMed.22811345.s13.e1" /><pair ddi="false" e1="DDI-PubMed.22811345.s13.e1" e2="DDI-PubMed.22811345.s13.e0" /></sentence><sentence text=" Similar studies show this interaction does not exist between PPIs and enteric-coated mycophenolic acid (EC-MPA)"><entity charOffset="86-103" id="DDI-PubMed.22811345.s14.e0" text="mycophenolic acid" /><entity charOffset="105-111" id="DDI-PubMed.22811345.s14.e1" text="EC-MPA" /><entity charOffset="108-113" id="DDI-PubMed.22811345.s14.e2" text="MPA" /><pair ddi="false" e1="DDI-PubMed.22811345.s14.e0" e2="DDI-PubMed.22811345.s14.e0" /><pair ddi="false" e1="DDI-PubMed.22811345.s14.e0" e2="DDI-PubMed.22811345.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22811345.s14.e0" e2="DDI-PubMed.22811345.s14.e2" /><pair ddi="false" e1="DDI-PubMed.22811345.s14.e1" e2="DDI-PubMed.22811345.s14.e1" /><pair ddi="false" e1="DDI-PubMed.22811345.s14.e1" e2="DDI-PubMed.22811345.s14.e2" /></sentence><sentence text=" Unfortunately, most of the available data evaluating this interaction are pharmacokinetic analyses that do not investigate the clinical impact of this interaction" /><sentence text="" /><sentence text="A significant interaction exists between PPIs and mycophenolate mofetil secondary to reduced dissolution of mycophenolate mofetil in higher pH environments"><entity charOffset="50-71" id="DDI-PubMed.22811345.s17.e0" text="mycophenolate mofetil" /><entity charOffset="108-129" id="DDI-PubMed.22811345.s17.e1" text="mycophenolate mofetil" /><pair ddi="false" e1="DDI-PubMed.22811345.s17.e0" e2="DDI-PubMed.22811345.s17.e0" /><pair ddi="false" e1="DDI-PubMed.22811345.s17.e0" e2="DDI-PubMed.22811345.s17.e1" /></sentence><sentence text=" EC-MPA is not absorbed in the stomach; therefore, low intragastric acidity does not impact EC-MPA and bioavailability is maintained with this formulation during PPI coadministration"><entity charOffset="4-24" id="DDI-PubMed.22811345.s18.e0" text="MPA" /><entity charOffset="95-115" id="DDI-PubMed.22811345.s18.e1" text="MPA" /><pair ddi="false" e1="DDI-PubMed.22811345.s18.e0" e2="DDI-PubMed.22811345.s18.e0" /><pair ddi="false" e1="DDI-PubMed.22811345.s18.e0" e2="DDI-PubMed.22811345.s18.e1" /></sentence><sentence text=" The clinical impact of this interaction is unknown, yet one can theorize that reduced exposure to MPA in SOT recipients can increase the risk of allograft rejection and/or failure"><entity charOffset="99-101" id="DDI-PubMed.22811345.s19.e0" text="MPA" /></sentence><sentence text="" /></document>